艾美捷科技代理Nexcelom品牌。

2003年，Nexcelom的创始人推出了CP2，这是一种辅助手动细胞计数的方便工具。Nexcelom的创始人兼首席技术官JeanQiu博士说，“NIH的某位客户曾要求我们‘消除显微镜计数’。

为此，我们发明了CellometerAutoT4，用于测量细胞浓度和活力。”自那时起，Nexcelom扩大了产品范围，升级了系统功能，并优化了适用的方法，使研究人员能够分析所有细胞类型，

包括小细胞和原代细胞。凭借先进的专有技术，Nexcelom是细胞分析中基于图像的细胞计数的领导者和创新者。世界各地的科学家在学术和政府研究机构、生物技术和工业环境中使用

Cellometer，Cellaca和Celigo仪器进行细胞定量、分析和基于细胞的检测。Nexcelom图像细胞术和细胞分析解决方案被集成到生命科学的广泛工作流程中。

Lunginnov公司位于法国里尔市，主要产品线包括生命科学试剂和体外诊断医疗器械。Lunginnov公司最大的特色是为研究者提供Endocan和CG-Cleaved Endocan检测产品（包括抗体、ELISA试剂盒、重组蛋白等），这两个分子已经被证明是肺部感染/损伤的标志分子。

Lunginnov develops innovative solutions for respiratory diseases that enable earlier therapeutic decision to be helpful for patients. Lunginnov markets 2 product lines:

A range of unique reagents for research in Life Sciences

A range of original medical devices for In Vitro Diagnostic

Lunginnov is declared manufacturer to the french regulatory agency ANSM. The company devotes a significant part of its budget to its internal R&D and to set up collaborative projects with Research Centers in France and abroad. Lunginnov is specialized on endocan and CG-cleaved endocan as markers of lung infection/injury, by proposing specific tools of high quality researchers and clinicians.

更多详情请联系 

艾美捷科技有限公司

全国服务热线：400-6800-868

邮箱：sales@amyjet.com

网站：www.amyjet.com

艾美捷科技特约代理Avidity Biosciences公司产品。

Avidity Biosciences公司位于美国加州La Jolla，是一家专门从事抗体寡核苷酸结合物（AOC™）技术开发的生物技术公司，此项技术结合了单抗组织选择性和寡核苷酸疗法的精确性，克服了寡核苷酸给药屏障。

Avidity Biosciences is a privately-held biotech company pioneering Antibody Oligonucleotide Conjugates (AOC™). AOCs combine the tissue selectivity of monoclonal antibodies and the precision of oligonucleotide-based therapeutics to overcome barriers to the delivery of oligonucleotides and target genetic drivers of disease.

Antibody oligonucleotide conjugate (AOC™) technology

Avidity’s antibody oligonucleotide conjugate (AOC™) technology utilizes antibodies to target cells and tissues of interest and facilitate the uptake and internalization of oligonucleotide payloads. By combining the cellular and tissue selectivity of antibodies with the selectivity and efficiency of oligo-based approaches, Avidity has demonstrated modulation of disease-related RNAs in diverse cell types and tissues including muscle, heart, liver, tumors and immune cells.